Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2778 results

Ad hoc release / Apr 28, 2026

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority…
Ad hoc release / Apr 28, 2026

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als…
Clinical Trials / Apr 24, 2026

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Clinical Trials / Apr 21, 2026

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Clinical Trials / Apr 16, 2026

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
Clinical Trials / Apr 16, 2026

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Clinical Trials / Apr 15, 2026

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Clinical Trials / Apr 14, 2026

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Clinical Trials / Apr 14, 2026

A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Clinical Trials / Apr 08, 2026

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)